CT-defined sarcopenia and outcomes in HR+/HER2− metastatic breast cancer treated with CDK4/6 inhibitors
Sarcopenia is increasingly recognized as a potential prognostic factor in patients with cancer, but its clinical significance in HR+/HER2− metastatic breast cancer treated with CDK4/6 inhibitors remains uncertain. This study investigated the association between CT-defined sarcopenia and clinical outcomes in this po...